UBC drug formulation receives $1.1 million for clinical development as HIV treatment
A drug delivery system developed through the University of British Columbia’s Neglected Global Diseases Initiative and licensed to iCo Therapeutics Inc. will receive $1.1 million from the National Research Council of Canada (NRC) for clinical development as a treatment for HIV patients.
Jun 5, 2012
